Open Access
Nucleotide Polymerase Inhibitor So fos bu vir plus Ribavirin for Hepatitis C
E.J. Gane,Catherine A.M. Stedman,Robert H. Hyland,Xiao Ding,Evguenia S. Svarovskaia,William T. Symonds,R. Hindes,M.M. Berrey +7 more
TLDR
Sofosbuvir plus ribavirin for 12 weeks may be effective in previously untreated patients with HCV genotype 1, 2, or 3 infection, and the rate of sustained virologic response 24 weeks after therapy is reported.Abstract:
BACKGROUND The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated so fos bu vir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for the treatment of HCV infection. METHODSread more
Citations
More filters
Journal ArticleDOI
Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
Gregory T. Everson,K. Sims,Maribel Rodriguez-Torres,Christophe Hézode,Eric Lawitz,Marc Bourlière,Véronique Loustaud-Ratti,Vinod K. Rustgi,Howard Schwartz,Harvey A Tatum,Patrick Marcellin,Stanislas Pol,Paul J. Thuluvath,Timothy Eley,Xiaodong Wang,Shu-Pang Huang,Fiona McPhee,Megan Wind-Rotolo,Ellen Chung,Claudio Pasquinelli,Dennis M. Grasela,David F. Gardiner +21 more
TL;DR: In a phase 2a study, the all-oral, interferon-free, and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 was well tolerated and achieved high rates of SVR12 in patients with HCV genotype 1 infection.
Journal ArticleDOI
APASL consensus statements and recommendation on treatment of hepatitis C
Masao Omata,Tatsuo Kanda,Lai Wei,Ming-Lung Yu,Wang-Long Chuang,Alaaeldin Ibrahim,Cosmas Rinaldi Adithya Lesmana,Jose D. Sollano,Manoj Kumar,Ankur Jindal,Barjesh Chander Sharma,Saeed Hamid,A. Kadir Dokmeci,Mamun-Al-Mahtab,G.W. McCaughan,Jafri Wasim,Darrell H. G. Crawford,Jia-Horng Kao,Osamu Yokosuka,George K. K. Lau,Shiv Kumar Sarin +20 more
TL;DR: Recommendations on treatment of hepatitis C are presented in this review after an international working party gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015.
Journal ArticleDOI
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
Eric G. Meissner,David Wu,Anu Osinusi,Dimitra Bon,Kimmo Virtaneva,Dan E. Sturdevant,Steve F. Porcella,Honghui Wang,Eva Herrmann,John G. McHutchison,Anthony F. Suffredini,Michael A. Polis,Stephen M. Hewitt,Ludmila Prokunina-Olsson,Henry Masur,Anthony S. Fauci,Shyamasundaran Kottilil +16 more
TL;DR: Results suggest that restoration of type I intrahepatic IFN signaling by EOT may facilitate HCV eradication and prevention of relapse upon withdrawal of SOF/RBV.
Journal ArticleDOI
Age and liver transplantation
François Durand,François Durand,Josh Levitsky,François Cauchy,Hélène Gilgenkrantz,Hélène Gilgenkrantz,Olivier Soubrane,Claire Francoz +7 more
TL;DR: Changing trends in recipient and donor age are summarised and age matching between the donor and the recipient should be incorporated into allocation policies with a multistep approach.
Journal ArticleDOI
The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold
TL;DR: This paper focuses on more recent developments, especially nucleoside analogues that contain more than one modification to the nucleosides scaffold, as well as many candidate compounds that encountered obstacles.
References
More filters
Journal ArticleDOI
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Dongliang Ge,Jacques Fellay,Alexander J. Thompson,Jason Simon,Kevin V. Shianna,Thomas J. Urban,Erin L. Heinzen,Ping Qiu,Arthur H. Bertelsen,Andrew J. Muir,Mark S. Sulkowski,John G. McHutchison,David Goldstein +12 more
TL;DR: It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
Journal ArticleDOI
Diagnosis, management, and treatment of hepatitis C: An update
TL;DR: This document has been approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.
Journal ArticleDOI
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
Michael J. Sofia,Donghui Bao,Wonsuk Chang,Jinfa Du,Dhanapalan Nagarathnam,Rachakonda Suguna,P. Ganapati Reddy,Bruce S. Ross,Peiyuan Wang,Hai-Ren Zhang,Shalini Bansal,Christine Espiritu,Meg Keilman,Angela M. Lam,Holly M. Micolochick Steuer,Congrong Niu,Michael J. Otto,Phillip A. Furman +17 more
TL;DR: Phosphoramidate prodrugs of the 5'-phosphate derivative of the β-d- 2'-deoxy-2'-α-fluoro-2-β-C-methyluridine nucleoside showed significant potency in the HCV subgenomic replicon assay and produced high levels of triphosphates 6 in primary hepatocytes and in the livers of rats, dogs, and monkeys when administered in vivo.
Journal ArticleDOI
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok,David F. Gardiner,Eric Lawitz,Claudia Martorell,Gregory T. Everson,Reem Ghalib,Robert Reindollar,Vinod K. Rustgi,Fiona McPhee,Megan Wind-Rotolo,Anna Persson,Kurt Zhu,Dessislava Dimitrova,Timothy Eley,Tong Guo,Dennis M. Grasela,Claudio Pasquinelli +16 more
TL;DR: This preliminary study involving patients with chronic HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virologic response can be achieved with two direct-acting antiviral agents only.
Journal ArticleDOI
Naturally occurring dominant resistance mutations to hepatitis c virus protease and polymerase inhibitors in treatment-naive patients
Thomas Kuntzen,Joerg Timm,Andrew Berical,Niall Lennon,Aaron M. Berlin,Sarah Young,Bongshin Lee,David Heckerman,Jonathan M. Carlson,Laura L. Reyor,Marianna Kleyman,Cory M. McMahon,Christopher E. Birch,Julian Schulze zur Wiesch,Timothy Ledlie,Michael Koehrsen,Chinnappa D. Kodira,Andrew Roberts,Georg M. Lauer,Hugo R. Rosen,Florian Bihl,Andreas Cerny,Ulrich Spengler,Zhimin Liu,Arthur Y. Kim,Yanming Xing,Arne Schneidewind,Margaret A. Madey,Jaquelyn Fleckenstein,Vicki M. Park,James E. Galagan,Chad Nusbaum,Bruce D. Walker,Bruce D. Walker,Gerond Lake-Bakaar,Eric S. Daar,Ira M. Jacobson,Edward D. Gomperts,Brian R. Edlin,Sharyne M. Donfield,Raymond T. Chung,Andrew H. Talal,Tony N. Marion,Bruce W. Birren,Matthew R. Henn,Todd M. Allen +45 more
TL;DR: Naturally occurring dominant STAT‐C resistance mutations are common in treatment‐naïve patients infected with HCV genotype 1, and their influence on treatment outcome should be characterized to evaluate possible benefits of drug resistance testing for individual tailoring of drug combinations when treatment options are limited due to previous nonresponse to peginterferon and ribavirin.